In murine tumor models CXCR2 blockade has been shown to modulate neutrophil trafficking to sites of chronic inflammation, subsequently reduced tumor and metastasis formation and enhanced treatment efficacy in distinct therapeutic conditions (38–41). This evidence concerns the gene CXCR2 and neoplasm.